)
Visual
test
Optomed
Optomed (OPTOMED) investor relations material
Optomed Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary10 Feb, 2026
Executive summary
Full-year 2025 revenue grew 13.7% to €17.1 million, driven by strong Devices segment performance and US market growth, while Q4 revenue declined 5.6% due to a large non-recurring order in the prior year.
Devices segment revenue surged 43.1% year-over-year, with significant US growth and recurring revenue from Aurora AEYE; Software segment revenue declined 2.5% due to lower non-healthcare consulting.
EBITDA for 2025 was -€3.5 million, with a margin of -20.6%, reflecting operating leverage and cost discipline.
A successful share issue in Q4 raised approximately €6 million, strengthening the balance sheet and supporting growth initiatives.
Large recurring revenue base established for Aurora AEYE, with continuous growth and new product launches such as Lumo.
Financial highlights
Q4 2025 revenue was €4.8 million, down 5.6% year-over-year; full-year revenue reached €17.1 million, up 13.7%.
Q4 gross margin: 61.5% (down from 65.1%); full-year gross margin: 63.6%.
Q4 EBITDA: -€1.3 million; full-year EBITDA: -€3.5 million.
Net loss for 2025: -€6.6 million; EPS: -0.34.
Cash and cash equivalents at year-end: €9.9 million.
Outlook and guidance
Revenue is expected to grow in 2026 compared to 2025, supported by recurring US revenue and ongoing Lumo sales, despite continued uncertainty and reduced predictability.
Growth uncertainties include weak software market in Finland, reduced visibility, and challenges in forecasting large capex deals.
Geopolitical and forex risks remain.
US market turbulence impact on 2026?
Accelerate Aurora AEYE sales cycle
Software segment non-healthcare consulting plan?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Optomed
- Q4 Devices revenue soared 149%, with FDA clearance fueling 2025 growth optimism.OPTOMED
Q4 20243 Dec 2025 - Devices segment drove 183.6% Q3 growth, while software declined and margins improved.OPTOMEDQ3 20256 Nov 2025
- H1 2025 revenue up 15.1% with Devices surging 49.5% and new AI device launched.OPTOMEDQ2 20257 Aug 2025
- Q3 revenue fell 26% as device sales slumped, but liquidity remains strong.OPTOMEDQ3 202413 Jun 2025
- Revenue fell, but cash and FDA clearance boost outlook amid China credit risks.OPTOMEDQ2 202413 Jun 2025
- Devices revenue up 71.5% and positive cash flow signal robust 2025 growth.OPTOMEDQ1 20255 Jun 2025
Next Optomed earnings date
Q1 20266 May, 2026
Optomed
Next Optomed earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage